Does Incremental Initiation of Haemodialysis Preserve Native Kidney Function?
NCT ID: NCT03418181
Last Updated: 2018-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2018-01-08
2019-03-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Most patients who commence haemodialysis start three times per week for 3.5-4 hours per session, irrespective of the amount of natural kidney function they may have. An alternative approach used in some kidney units is to take account of the natural kidney function in prescribing the amount of dialysis. This may allow patients to start treatment needing to spend less time on dialysis or even to start just twice weekly. The amount of dialysis can be adjusted over time as natural kidney function declines. This is called "incremental haemodialysis". Both of these approaches are considered to be standard care although it is not known which approach is more beneficial to patients.
There are some suggestions that the frequency of dialysis may influence the rate of decline of natural kidney function but this need to be tested in a large randomised study. To inform the design of such a study, a smaller scale feasibility study is required.
We intend to randomise fifty new starters on haemodialysis with adequate natural kidney function into two groups - a group who will have dialysis prescribed in the standard fashion - three times weekly for 3.5-4 hours per session or a group who will have an incremental start beginning with twice weekly treatment. We will investigate how many patients have sufficient natural kidney function to be eligible, whether patients are willing to participate and continue in the study, compare the rate of loss of kidney function between groups, and ascertain whether this individualised dialysis approach is less intrusive to patients. The results will be used to design a larger definitive study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Extended Haemodialysis Treatment Duration in Patients With End-stage Renal Disease
NCT01721421
Individualized Incremental Hemodialysis Study
NCT03352271
A Feasibility Study to Test the Acceptability, Tolerance and Safety of Incremental Haemodialysis
NCT04268264
Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
NCT03874117
RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis (REAL-LIFE)
NCT04360694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
50 patients who have newly started on haemodialysis will be recruited into the study from 4 UK centres.
Eligible patients will be approached prior to initiation of dialysis or after starting dialysis. The details of the study will be explained to them and a Patient Information sheet will be provided. Interested participants will be invited to the study and a written consent will be obtained.
The participants will be randomly allocated to 2 groups.
1. Thrice weekly dialysis (control arm)
2. Incremental dialysis - Twice weekly dialysis to start with and slowly increasing the duration and frequency of dialysis to thrice weekly depending on their native kidney function.
All participants will be monitored at least once monthly by performing dialysis related blood tests, urine tests, clinical evaluation, medications, weight, dialysis adequacy, adverse events.
Questionnaire involving quality of life, mood, illness intrusiveness, functional status, cognitive function will also be performed.
Participants will be recruited in the first year and all participants will be followed up for 12 months. All participants may withdraw at any time without any change in their dialysis care.
To ensure independence, the University of Hertfordshire will perform randomisation, and assist with data monitoring and data analysis.
A 6 month rate of loss of native kidney function between the 2 groups will be analysed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
1. Thrice weekly dialysis (control arm)
2. Incremental dialysis - Twice weekly dialysis to start with and slowly increasing the duration and frequency of dialysis to thrice weekly depending on their native kidney function.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Haemodialysis
Thrice weekly dialysis (control arm) - dialysis dose will not be adjusted according to Residual Kidney Function and subjects will be dialysed initially for 3.5-4 hours thrice weekly to ensure a target minimum eKt/V of 1.2.
Standard Haemodialysis
Thrice weekly dialysis.
Incremental dialysis
Twice weekly dialysis - dialysis dose will be adjusted according to Residual Kidney Function.
Patients will commence dialysis for 3.5-4 hours twice weekly and have residual renal urea clearance formally measured by interdialytic urine collection at the end of the week following dialysis initiation. Subsequent to this, dialysis dose will be adjusted.
Incremental dialysis
Individualised dialysis dose according to native kidney function.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard Haemodialysis
Thrice weekly dialysis.
Incremental dialysis
Individualised dialysis dose according to native kidney function.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Advanced renal failure due to underlying primary kidney disease and established as a new starter on haemodialysis within the previous 3 months
* Residual Kidney Function likely to permit twice weekly dialysis as defined by interdialytic urea clearance ≥3ml/min/1.73m2 BSA measured routinely as part of standard care
* Sufficient understanding of the study procedures and requirements including capacity for explicit agreement to be randomised to standard or incremental HD regimens
Exclusion Criteria
* Anticipated requirement for high-volume ultrafiltration on dialysis (e.g. subjects with daily enteral or parenteral nutrition)
* Blood-borne virus positivity
* Subjects unable to comply with requirement for monthly interdialytic urine collection.
* Pregnancy
* Prognosis \<12 months as judged by PI
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Hertfordshire
OTHER
East and North Hertfordshire NHS Trust
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Enric Vilar
Role: PRINCIPAL_INVESTIGATOR
East and North Hertfordshire NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East and North Hertfordshire NHS Trust (incorporating Mount Vernon Cancer Centre)
Stevenage, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dr Enric Vilar
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Kaja Kamal RM, Farrington K, Wellsted D, Sridharan S, Alchi B, Burton J, Davenport A, Vilar E. Impact of incremental versus conventional initiation of haemodialysis on residual kidney function: study protocol for a multicentre feasibility randomised controlled trial. BMJ Open. 2020 Aug 13;10(8):e035919. doi: 10.1136/bmjopen-2019-035919.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RD2017-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.